FDA Advisory approves Lilly's CYRAMZA (ramucirumab) for type of lung Cancer Medical Dialogues Bureau1 March 2020 8:30 AM GMTThe ODAC considered the safety and efficacy data from the Phase 3 RELAY trial, which is the basis for the CYRAMZA supplemental Biologics License...
Eli Lilly gets USFDA nod for Cyramza to treat hepatocellular carcinoma Medical Dialogues Bureau14 May 2019 4:17 AM GMTThe USFDA has removed the boxed warning from the CYRAMZA labelling which highlighted warnings pertaining to haemorrhage, gastrointestinal perforation...